We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy of RetroNectin-Activated Cytokine-Induced Killer Cell Therapy in Metastatic Brain Tumor Patients.
- Authors
Li, Wei; Wang, Yaomei; Zhao, Lingdi; Xu, Linping; Zhang, Yong; Mai, Ling; Gao, Quanli
- Abstract
Background: The aim of this study was to investigate the clinical efficacy of RetroNectin-activated cytokine-induced killer cell (R-CIK) therapy following conventional therapies in patients with metastatic brain tumors. Methods: This study included 20 patients with metastatic brain tumors. Patients received R-CIK therapy following conventional therapies (including chemotherapy and target therapy). Progression-free survival (PFS), overall survival (OS), and prognostic factors were evaluated. Results: Of the 4 breast cancer patients in our cohort, 2 remained alive and 2 died. Of the 14 non-small cell lung cancer (all adenocarcinoma) patients, 3 had a partial response, 8 had stable disease, and 3 had progressive disease after receiving R-CIKs. The overall response rate was 21.4% (3/14), and the disease control rate was 78.6% (11/14). The median PFS and OS were 7.7 months (95% confidence interval (CI) 3-16.5 months) and 12.6 months (95% CI 6-21 months), respectively. Conclusion: R-CIKs combined with conventional therapies could improve the prognosis of metastatic brain tumor patients, especially of those with adenocarcinoma of the lung. © 2015 S. Karger GmbH, Freiburg
- Publication
Oncology Research & Treatment, 2015, Vol 38, Issue 4, p160
- ISSN
2296-5270
- Publication type
Article
- DOI
10.1159/000380890